Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5663206
Reference Type
Journal Article
Title
The proliferation and migration effects of huangqi on RSC96 Schwann cells
Author(s)
Fang, WK; Ko, FY; Wang, HL; Kuo, CH; Chen, LM; Tsai, FJ; Tsai, CH; Chen, YS; Kuo, WW; Huang, CY
Year
2009
Is Peer Reviewed?
1
Journal
The American Journal of Chinese Medicine
ISSN:
0192-415X
Volume
37
Issue
5
Page Numbers
945-959
Language
English
DOI
10.1142/S0192415X09007363
Abstract
This study evaluated the proliferation effects of huangqi on neuron regeneration. We investigated the molecular mechanisms, which include: (1) cyclin D1, A, E-cell cycle factors and MAPK signaling proliferation (2) FGF-2-UPA-MMPs migration signaling. After treatment with various Huanqi concentrations (1.25, 12.5, 125, 250 and 500 microg/ml,), we observed that Huanqi can increase Rsc 96 cell proliferation at 12.5 microg/ml (p < 0.01) concentration determined by the MTT and wound healing tests. Examination by RT-PCR and Western blotting assay showed that Huangqi is able to stimulate the mRNA and protein expressions of cyclin D1, A, E, cell cycle controlling proteins and excite ERK and P38 MAPK signaling pathways to promote cell proliferation. Huangqi stimulates the FGF-2-UPA-MMP 9 migration pathway and enhances RSC 96 Schwann cells migration. Using MAPK chemical inhibitors, U0126, SB203580 and SP600125, the proliferative effects of Huangqi on RSC 96 cells were ERK and P38 signaling-dependent. Based on these results, applying an appropriate dose of Huangqi with biomedical materials would be a potential approach to enhancing neuron regeneration.
Keywords
Animals; Anthracenes/pharmacology; Astragalus Plant; Blotting, Western; Butadienes/pharmacology; Cell Line; Cell Movement/drug effects; Cell Proliferation/drug effects; Cell Survival/drug effects; Cyclin A/genetics/metabolism; Cyclin D1/genetics/metabolism; Cyclin E/genetics/metabolism; Dose-Response Relationship, Drug; Drugs, Chinese Herbal/pharmacology; Enzyme Inhibitors/pharmacology; Fibroblast Growth Factor 2/genetics/metabolism; Imidazoles/pharmacology; Matrix Metalloproteinase 9/genetics/metabolism; Mitogen-Activated Protein Kinase 3/antagonists & inhibitors/genetics/metabolism; Models, Biological; Nitriles/pharmacology; Pyridines/pharmacology; Reverse Transcriptase Polymerase Chain Reaction; Schwann Cells/cytology/drug effects/metabolism; Urokinase-Type Plasminogen Activator/genetics/metabolism; p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/genetics/metabolism; 103107-01-3; 136601-57-5; 1TW30Y2766; 922OP8YUPF
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity